 Oncorus shares have been in steady decline since nearly doubling in value less than six months after the companys October 2020 IPO. Current trading price of 13 is slightly under the 15 IPO price, but the biotech has just entered the clinic with its first viral oncolytic therapy, ONCR-177. 